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7ABSTRACT
Rheumatoid arthritis (RA) is an inflammatory disorder characterized by synovial cell
proliferation and microvascular injury. RA often leads to permanent articular cartilage
damage because the inflamed synovium is an abundant source of cytokines and enzymes
harmful to the articular cartilage. If repeated intra-articular corticosteroid treatments fail to
control synovial inflammation, surgical, chemical, and radiation synovectomy (RSYN)
with different radioactive preparations have been used to arrest the inflammation and the
progression of cartilage degeneration. In this experimental study, the normal joints of
rabbits and horses were investigated to assess the effects of RSYN with a relatively new
radiopharmaceutical, holmium-166 ferric hydroxide macroaggregate (166Ho FHMA), to
determine whether it would be a suitable candidate for therapeutic use in humans, and
possibly also in horses.
The treated joints were injected with radioactive 166Ho FHMA and the control joints with
nonradioactive 165Ho FHMA. Both in rabbits and horses, radioactive 166Ho FHMA
markedly suppressed the synovial lining hyperplasia compared with control joints. In
addition, multifocal necrosis of the synovial lining, neovascularization, and eventually
subsynovial fibrosis were seen in the joints treated with 166Ho FHMA. In rabbits, the
pattern of multifocal synovial necrosis as well as the intra-articular distribution of radioac-
tivity in the autoradiography images suggested an uneven distribution of 166Ho FHMA
within the joint. Autoradiography analysis of lapine knees showed some leakage of
radioactivity 3 days postinjection. In horses, 166Ho FHMA treatment caused reactive
synovitis in fetlock joints. A large dose of strong beta-emitter 166Ho resulted in excessive
radiation injury and local pain. Joint fluid analysis of horses showed very little residual
radioactivity 5 days after RSYN; 166Ho FHMA had probably been effectively cleared from
the synovial fluid by the synovium. Scintigraphic examination revealed no extra-articular
leakage of radioactivity. Increased synovial fluid protein levels after RSYN indicated radi-
ation-induced soft-tissue injury and leakage of plasma into the synovial fluid from the
vasculature. Synovial restoration in rabbit knees was evident 2 months after 166Ho FHMA,
whereas equine synovium had regenerated poorly. 
The composition and morphology of adult articular cartilage in both species were not
markedly affected by 166Ho FHMA treatment. Young rabbit cartilage showed mild radia-
tion-induced fibrillation of the cartilage surface after 166Ho FHMA treatment but no
further breakdown of the collagen framework during the 1-year follow-up. Active 35S
sulfate incorporation indicated normal chondrocyte metabolism in all zones of the carti-
lage. Only transient irradiation-induced derangement of matrix production was seen in
young rabbits, and transient downregulation of collagen synthesis in horses.
Overall, suppression of synovial hyperplasia, little extra-articular leakage, and only minor
effects on articular cartilage suggest that RSYN can be used in clinical management of
arthritis in man and horses provided that untoward side-effects are avoided.
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ADAMTS adamalysin subfamily of metalloproteinases
AIA antigen-induced arthritis
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EDTA ethylenediaminetetraacetic acid
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FHMA ferric hydroxide macroaggregate
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IL-1 interleukin-1
MCP metacarpophalangeal joint
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RNA ribonucleic acid 
rRNA ribosomal RNA
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INTRODUCTION
In human rheumatoid arthritis (RA), when medical treatment fails, surgical, chemical, and
radiation synovectomy (RSYN) have been cited as palliative treatments (Cruz-Esteban &
Wilke, 1995; Gibbons et al., 2002).  Synoviorthesis is used synonymously with RSYN;
this term was originally adopted by French authors to reter to restoration of the synovium
(Delbarre & Menkes, 1974). In the 1960s, radioactive gold-198 (198Au) was applied to
treat RA in human patients, but currently the most widely reported radiopharmaceutic for
joint therapy is yttrium-90 (90Y) colloid (Fellinger & Schmid, 1952; Virkkunen et al.,
1967; Clunie & Ell, 1995). The procedure entails injection of a  emitting radiopharma-
ceutic directly into the joint to control and ablate inflammation (Ansell et al., 1963).
Radiopharmaceutics, usually colloids or aggregates, are assumed to be quickly phagocy-
tosed by synoviocytes and then distributed within the synovium, primarily at the surface
(Ingrand, 1973). Diseases of the synovium can result in increased vascularization,
edema, synovial layer proliferation, lymphocytic infiltration, and fibrosis (Johansson &
Rejno, 1976). The objective of RSYN is to limit the inflammatory reaction. RSYN has
been described as an effective local treatment for RA, hemophilic arthritis, and recurrent
synovitis in human patients who have not responded to medical therapy (Jahangier et al.,
2001; Siegel et al., 2001). Once the inflamed synovium is destroyed by direct radiation,
the regenerated synovium is free of disease. Dosing of radiopharmaceutics is still based
more on clinical experience than on experimental studies, and the exact dose required of
a given radiopharmaceutic to achieve effective synovectomy remains unclear (Deutsch
et al., 1993).
Synovial regeneration has been reported to occur within 6-9 weeks following RSYN in
rabbits (Pavelka et al., 1975). The articular cartilage may sustain some degree of enzymat-
ic degradation, which continues until synovial regeneration is complete (Mitchell &
Cruess, 1967b). Traumatic injury of the synovial membrane can lead to chronic synovitis
(Richardson, 2002) and contribute to the degenerative process by release of substances
directly or indirectly harmful to the cartilage such as matrix metalloproteinases,
prostaglandin E2, free radicals, and cytokines (Palmer & Bertone, 1994).  RSYN has been
claimed to predispose the treated joint to radiation-induced chondrocyte injury and subse-
quent osteoarthritis (OA) (Pavelka et al., 1975; Meier-Ruge et al., 1976; Kerschbaumer et
al., 1979). However, the risk of radiation-induced cartilage injury is generally considered
small relative to the destruction induced by the evolution of the rheumatoid synovitis itself
(Meier-Ruge et al., 1976).
Rabbits are the preferred animal for studying RSYN. Normal animals have been used to
study leakage, dosimetry, and radiation-induced damage to articular cartilage (Deutsch et
al., 1993). RSYN in humans is performed to treat recurrent synovitis to reduce the ongoing
inflammation that promotes degradative changes in articular cartilage (Smith, 1999).  The
chronic arthritis produced by intra-articular injections of soluble protein antigens into
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previously immunized rabbits (antigen-induced arthritis, AIA) provides an animal model
that mimics RA (Paget & Gibofsky, 1979). Considerable differences do, however, exist
between lapine AIA and human RA, and the effects of RSYN on AIA must be interpreted
with caution (Deutsch et al., 1993; Hembry et al., 1993). In retired racehorses, natural
degeneration of cartilage is expected because of their previous racing careers. The dorsal
aspect of the fetlock joint in racehorses is especially vulnerable to injury during active
training and racing (Pool, 1996). Thus, our study on horses provides a model for early
naturally occurring degenerative joint disease.
Several new radionuclides and carriers have recently been studied for treatment of vari-
ous joint disorders (O'Duffy et al., 1999; Shin et al., 2001; Ofluoglu et al., 2002; Lee et
al., 2003a). Holmium-166 (166Ho) is a radionuclide with excellent physical properties for
synovectomy. A reasonably short half-life (1.1 days) ensures effective synovectomy
without increased risk of unwanted radiation burden to normal organs. Betaradiation
energy for radiosynovectomy (max 1.8 MeV) is suitable for depositing a substantial
dose to the thickened synovium. The physical properties enable 90% of the radiation to
penetrate to a depth of 2 mm in the thickened synovium (Johnson & Yanch, 1991). Ioniz-
ing  radiation (81 keV) increases only slightly the total radiation to the body. A stable
daughter is formed after radioactive decay. 166Ho is bound to ferric hydroxide macroag-
gregate (FHMA) particles, which are small enough to be easily phagocytosed by the
synovium but large enough to be retained in the joint (Hnatowich et al., 1978; Noble et
al., 1983; Davis & Chinol, 1989).
RSYN has been shown to control clinical symptoms of RA in man during follow-up
periods of longer than a year (Sledge et al., 1986; Zuckerman et al., 1987; Will et al.,
1992). Moreover, a retrospective study of racehorses has claimed better racing results
after arthroscopic synovectomy (Roneus et al., 1997), but only two experimental studies
exist on the use of RSYN with samarium-153 hydroxyapatite  microsphere (153Sm M) in
equine medicine (Yarbrough et al., 2000a, 2000b). Our experimental study assesses the
effects of 166Ho FHMA on the synovium and cartilage of normal rabbits and horses. 
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REVIEW OF THE LITERATURE
1. Anatomy and physiology of the synovial joint
1.1. Joint capsule
The joint capsule of a synovial or diarthrodial joint consists of a thick fibrous portion and
a synovial membrane. The fibrous layer of the capsule comprises a dense tissue containing
moderate amounts of collagen and elastic fibers. The fibrous layer contributes to the
mechanical stability of the joint. The synovial membrane contains two mesenchymal
layers, the subintimal, and the intima. The subintima is adjacent to the fibrous layer and is
composed of fibrous, areolar, or adipose tissue depending on the function of and location
within the joints. The intima is composed of a 1- to 3- cell-thick synoviocyte layer with no
basement membrane. Synoviocytes consist of cells that have both secretory and phagocyt-
ic functions. Synoviocytes that phagocytose and pinocytose are type A or macrophage-like
cells. Type B or fibroblast-like cells secrete hyaluronan and lubricin into the synovial fluid
(Henderson, 1988). These molecules provide high viscosity to the synovial fluid (Poole et
al., 2001). Synovial lining cells have been suggested to be regarded not as different cell
entities but rather as different functional stages of cells (Henderson, 1988). 
1.2. Synovial fluid
In healthy joints, a small volume of synovial fluid - a colorless or pale-yellow viscous
liquid - occupies the intra-articular space. Synovial fluid is an ultrafiltrate of plasma. Most
elements, except hyaluronan and lubricin, are derived from the blood. Synovial fluid
contains mostly mononuclear cells (synoviocytes, monocytes, and lymphocytes), and the
remainder of the cells are polymorphonuclear leukocytes. Normal equine synovial fluid
contains <500 nucleated cells/l (Todhunter, 1996). Chondrocytes in mature animals
obtain their nutrients by diffusion from the synovial fluid (Hodge & McKibbin, 1969;
Maroudas, 1970). 
1.3. Articular cartilage
The articular cartilage is a hyaline cartilage. In the synovial joint, the hyaline cartilage
forms a frictionless articulating surface that allows movement and transfer of loads
between bones. Articular cartilage is mainly composed of an avascular and aneural extra-
cellular matrix. The extracellular matrix contains water, collagen, proteoglycans, and
other noncollagenous proteins. 
Cartilage is divided into superficial, intermediate, and deep zones. The zones can be
distinguished from one another by the varying arrangement of their cells and differences
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in their matrix. In the superficial zone, the chondrocytes are flattened and parallel to the
cartilage surface. Thin collagen fibrils are arranged parallel to the articular surfaces. In this
zone, the large proteoglycan aggrecan is present in its lowest concentration (Poole et al.,
2001). The superficial collagen fibers provides the highest tensile properties found in artic-
ular cartilage (Akizuki et al., 1986). The intermediate zone consists of rounded cells
surrounded by an extensive extracellular matrix rich in proteoglycan aggrecan. Collagen
fibrils are arcading, like branches on a tree. In the deep zone, the cell volume is at its
lowest, and cells are often grouped in clusters. The collagen fibrils are larger and predomi-
nantly perpendicular to the surface. Aggrecan content is at a maximum in this deep zone.
Adjacent to the zone and most remote from the articular surface, is the calcified zone. This
calcified zone is separated microscopically from the uncalcified cartilage by a distinct line,
the tidemark.
1.3.1 Chondrocytes
Chondrocytes are situated amongst an extensive extracellular matrix and have a cell
volume that averages only 2% of the total tissue volume in articular cartilage of human
adults (Stockwell & Meachim, 1979). All chondrocytes are surrounded by a narrow peri-
cellular region that contains proteoglycans and minor collagens. This organization of the
chondrocyte and its pericellular matrix is known as a chondron. The chondrons are
surrounded by a territorial region that is present throughout the cartilage (Poole et al.,
2001). The territorial regions are scattered in the interterritorial matrix, where the proteo-
glycan concentration is lower than in the territorial matrix. The turnover of matrix is regu-
lated by chondrocytes under the control and influence of growth factors, cytokines, and
mechanical stimuli (Poole, 1993).
1.3.2. Collagens
Type II collagen (90%) predominates in the articular cartilage. About half of the dry
weight of the articular matrix is made of type II collagen, except in the superficial zone,
where it accounts for most of the dry weight. The biosynthesis of type II collagen begins
with activation of the Col21 gene. During intracellular synthesis three identical 1(II)
chains wind round each other to form a triple helix. This procollagen molecule is stabilized
by interchain hydrogen bonds between the 1(II) chains. Extracellular conversion of a
procollagen to a tropocollagen molecule necessitates the cleavage of amino and carboxy
terminal propeptides, which border the procollagen molecule. In the amino and carboxy
telopeptide domains, covalent crosslinks form between lysine residues in adjacent chains,
making type II collagen fibrils very resistant to degradation (Poole et al., 2001). During
fibril formation the tropocollagen molecules are arranged in a quarter-staggered array. The
collagen framework is built before maturation; and adult articular cartilage has a limited
capacity for repair.  
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Several minor collagens, especially types IX and XI, account for 10% of the total collagen
content (Mendler et al., 1989). Minor collagen type IX is located on the surface of type II
collagen fibrils, whereas type XI collagen is present both in the center of collagen fibrils
and on fibril surfaces (Mendler et al., 1989). Both type IX and type XI increase the
mechanical stability of the type II fibrillar network (Kuivaniemi et al., 1997; Blaschke et
al., 2000).
1.3.3. Proteoglycans
Large proteoglycan aggregates are trapped in the collagen fibril network, and the integrity
of this network is essential in retaining aggrecan molecules in the cartilage. The proteo-
glycan content accounts for about 25% of the dry weight of the cartilage matrix. The
proteoglycans of articular cartilage fall into two broad categories: large aggregating
proteoglycans and small proteoglycans. The rest are aggrecan degradation products which
accumulate with age. The main proteoglycan, aggrecan, makes up 50-85% of the total
proteoglycan mass. Aggrecan content is relatively poor in the superficial zone. Its concen-
tration increases with increasing depth (Bayliss, 1986). The aggrecan core protein, a
polypeptide that is about 2000 amino acids long, contains three globular domains. Two
globular domains (G1 and G2) are at the hyaluronan-associated end. Aggrecan binds
through its amino terminal G1 globular domain to hyaluronan (Poole et al., 2001). This
binding is stabilized by the link protein. The majority of sulfated glycosaminoglycans
(GAGs) are contained within an extended region situated between the G2 and G3
domains. A single aggrecan molecule includes approximately 100 chondroitin sulfate and
30-50 keratan sulfate side chains, and also 60-70 O- and N-linked oligosaccharides.
Aggrecan shows an age-related decrease in size and enrichment in keratan sulfate relative
to chondroitin sulfate. The carboxyterminal G3 domain might be of importance in binding
to other molecules and regulating intracellular trafficking and processing of aggrecan
(Halberg et al., 1988; Zheng et al., 1998). Biosynthesis of aggrecan starts in the rough
endoplasmic reticulum with translation of gene transcripts for aggrecan core protein,
followed by N-linked glycosylation and addition of keratan sulfate and chondroitin
sulfate chains in the Golgi apparatus. After the GAG chains have been added, the proteo-
glycan molecules are transported to the plasma membrane and released into the pericellu-
lar matrix.
Hyaluronan, a nonsulfated GAG consisting of repeated N-acetylglucosamine and -glucuronic
acid molecules, is built as a free chain on the plasma membrane. Binding of several
proteoglycan monomers to a single hyaluronan molecule results in a large aggregate that
is trapped in the collagen fibril network. The binding of aggrecan monomers on hyaluro-
nan occurs extracellularly. Water is bound to aggrecans, forming a gel-like structure in
which water comprises up to 65-80% of the matrix volume. Glycosaminoglycans are
highly negatively charged carbohydrate chains, and aggrecans can bind up to 50 times
their weight in water. Cartilage has a tendency to swell, which is resisted by the collagen
network. The presence of water in association with the hydrophilic and negatively
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charged GAGs contributes to the compressive resilience of the articular cartilage
(Kempson, 1975).
The small proteoglycan molecules only constitute 1-4% of the total mass of proteoglycans
in articular cartilage, although they maybe as numerous as the large aggregating proteogly-
cans. Articular cartilage has been shown to contain at least four small proteoglycans, all of
which are members of a small leucine-rich proteoglycan (SLRP) gene family (Iozzo,
1997). The SLRPs recognized in articular cartilage are biglycan, decorin, fibromodulin,
and lumican. An important function of SLRPs seems to be the regulation of collagen fibril-
logenesis (Vogel et al., 1984; Hedbom & Heinegård, 1993; Scott, 1996; Svensson et al.,
1999; Reed & Iozzo, 2002).
2. Synovitis and arthritis 
2.1. Synovitis
Virtually every racehorse has one or more episodes of primary capsulitis and synovitis
during their racing career (McIlwraith, 1987). Characteristic clinical findings include heat,
effusion, and pain with flexion of joints (Richardson, 2002). Primary synovitis in horses is
characterized by inflammation of the synovium without gross disturbance of articular
cartilage or disruption of major supporting structures (Todhunter & Lust, 1990). Primary
synovitis is especially common in the metacarpophalangeal joint (Richardson, 2002).
Ligamentous instability, trauma, or degeneration of the articular cartilage can lead to
secondary synovitis (Todhunter & Lust, 1990). Microscopic changes in inflamed equine
joints include increased vascularization, edema, infiltration of mononuclear cells, and
hypertrophy and hyperplasia of the synoviocytes (Johansson & Rejno, 1976). 
An inflamed synovial membrane has the ability to induce damage to the articular cartilage
(Fell & Jubb, 1977). The main destructive mediators are interleukin-1 (IL-1) and tumor
necrosis factor alpha (TNF-) (Goldring, 2000; Bertone et al., 2001). IL-1 and TNF- are
produced by synoviocytes, mononuclear cells, and chondrocytes (Goldring, 2000). Cellu-
lar production of IL-1 and TNF- requires an appropriate stimulus by bacteria, immune
complexes, aggregated antibodies, matrix components, or lymphokines (Paget & Gibof-
sky, 1979; Sumi et al., 1986; Dinarello, 1988; Hardy et al., 1998; Homandberg, 1999;
Kagari et al., 2003). The action of IL-1 alone or together with TNF- on articular cartilage
is multifaceted, with many different gene products being influenced either by stimulation
or by suppression (van den Berg, 1999; Bertone et al., 2001). Catabolic cytokines can
significantly upregulate matrix metalloproteinase (MMP) gene expression (Richardson &
Dodge, 2000; Fernandes et al., 2002). These MMPs are the major enzymes involved in
early structural changes in cartilage (Pelletier et al., 2001). The expression of inducible
nitric oxide synthase, cyclooxygenase-2 (Cox-2), and phospholipase A2 is increased by
OA chondrocytes when stimulated by IL-1 alone or in combination with TNF- (Goldring,
2000). Products of these enzymatic activities, particularly nitric oxide and E-series
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prostaglandins, have been associated with cartilage injury (Blanco et al., 1995; Hashimoto
et al., 1998; Bertone et al., 2001; Kim et al., 2003).
Increased IL-1 levels are present in synovial fluid from osteoarthritic and inflamed equine
joints (Morris et al., 1990; Alwan et al., 1991b; Theoret et al., 1998; Bertone et al., 2001).
In humans, the level of TNF- was found to be higher in synovial fluid obtained from
rheumatoid joints than from osteoarthritic joints (Hopkins & Meager, 1988). Cytokines
can reduce matrix synthesis at much lower concentrations than those needed to stimulate
degradation (Poole, 1993). IL-1 inhibits both collagen and proteoglycan synthesis in
young cartilage, while old cartilage is significantly less responsive (Nietfeld et al., 1990;
MacDonald et al., 1992; Richardson & Dodge, 1997). IL-1 and TNF- can also induce
concomitant production of IL-6 and chemokine IL-8 (Pelletier et al., 1993; Goldring,
2000). Synovial fluid IL-6 concentration has been recognized as an excellent indicator of
naturally acquired disorder in the equine joint (Bertone et al., 2001). Proinflammatory IL-
8 plays an important role in acute inflammatory reaction; it attracts neutrophils and gener-
ates reactive oxygen metabolites (Djeu et al., 1990, Fernandes et al., 2002). 
2.2. Enzymatic degradation of the extracellular matrix
The functional capability of articular cartilage rests with maintaining the content and
structure of the principal extracellular molecules, collagen, and proteoglycan. In OA, both
aggrecan and type II collagen are degraded by proteolytic attack induced by degradative
cytokine IL-1 (Smith, 1999; Mort & Billington, 2001). The major proteases involved in
early cartilage degradation are MMPs and aggrecanases. Other enzymes, such as
stromelysins, gelatinases, and catephins, are also involved, but primarily as activators of
MMPs (Pelletier et al., 2001).
Collagen fibrils are very resistant to most proteinases and only a few proteinases, known
as collagenases, are capable of cleaving the triple helix. Collagenases belong to a group of
MMPs which initiate the breakdown of native collagens by denaturating or unwinding the
triple helix (Shingleton et al., 1996; Shlopov et al., 1997). They are a group of zinc-
dependent endopeptidases involved in the physiological turnover of the extracellular
matrix at neutral pH (Birkedal-Hansen et al., 1993). They are secreted as latent proen-
zymes and activated extracellularly (Goldring, 2000). Rodent interstitial collagenase
(MMP-13), neutrophil collagenase (MMP-8), interstitial collagenase (MMP-1), and
membrane type 1 MMP (MMP-14) are known to cleave the triple helix of the collagen
molecule (Shingleton et al., 1996; Goldring, 2000). Evidence suggests that MMP-13 is the
most important proteinase responsible for the resorption cartilage in osteoarthritis (Poole
et al., 2003b).
The aggrecanases (adamalysin subfamily of metalloproteinases; ADAMTS proteinases)
play a pivotal role in chondrocyte-mediated aggrecan cleavage. Currently three aggre-
canases, ADAMTS-1, ADAMTS-4, and ADAMTS-5, are known to cleave  aggrecan
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during the development of arthritis (Mort & Billington, 2001; Nagase & Kashiwagi,
2003). Recently, the role of IL-1 in mediating degradation of aggrecan by the aggrecanases
has been studied extensively (Arner, 2002; Nagase & Kashiwagi, 2003).
Collagenases are not the only metalloproteinases associated with early cartilage structural
changes. Stromelysin-1 (MMP-3) can cleave aggrecan molecules and is an important acti-
vator of latent collagenases (Murphy et al., 1987; Milner et al., 2001). An increase in
gelatinase A (MMP-2), gelatinase B (MMP-9), and matrilysin (MMP-7) expression has
been shown in osteoarthritic cartilage (Imai et al., 1997; Tsuchiya et al., 1997; Ohta et al.,
1998). Cathepsins B, D, and L contribute to further degradation of various matrix compo-
nents (Mort & Billington, 2001). 
A complex array of regulatory mechanisms and endogenous inhibitors is normally suffi-
cient to restrict the activity of any extracellular proteinase (Dean et al., 1989; Martel-
Pelletier et al., 1994). Amongst these are tissue inhibitors of metalloproteinases which bind
to the active site of the MMP and inhibit its catalytic activity. In OA and RA, evidence
indicates an imbalance between MMPs and their natural inhibitors that contributes to the
cartilage degradation (Martel-Pelletier et al., 1994; Reynolds, 1996).      
2.3. Osteoarthritis
In humans, osteoarthritis is defined as noninflammatory arthropathy (Hedbom & Hausel-
mann, 2002). The pathogenesis of OA includes mechanical, biochemical, and genetic
factors that contribute to the imbalance between cartilage matrix degradation and synthesis
(Goldring, 2000). Independent of the initiating factor, enzymatic degradation is now
recognized as a central feature of OA (Ishiguro et al., 2002; Caron, 2003). Chondrocytes
and synoviocytes are the main sources of enzymes responsible for cartilage breakdown
(Hollander et al., 1995; Vankemmelbeke et al., 1998). 
A functional collagen fibrillar network is essential for healthy articular cartilage since
there is no indication of extensive cartilage repair once the collagen fibrils are broken
down (Poole et al., 2001). In early OA, type II collagen damage is restricted to pericellular
and superficial sites (Wu et al., 2002). Superficial collagen damage leads to fibrillation
(Hollander et al., 1994) and increased water content of the cartilage surface (Brocklehurst
et al., 1984). Clonal formation of chondrocytes is often observed (Ishiguro et al., 2002). In
more advanced OA, increased bone formation is characterized by periarticular osteophyte
formation and sclerosis of subchondral bone. Cleavage of the collagen network results in
progressive loss of cartilage, causing deep fibrillation and vertical clefts. Calcification leads
to formation of new tidemarks and, finally, degenerative changes result in a complete loss of
articular cartilage, exposing the underlying subchondral bone (Buckwalter & Martin, 1995). 
Although degradation of the collagen network is an essential prerequisite for OA,
enhanced loss of proteoglycans is also closely associated with destruction of articular
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cartilage (Ishiguro et al., 2002). The sites of early type II collagen damage and loss of
proteoglycan coincide (Hollander et al., 1995). The loss of proteoglycans imposes an
increasing load on collagen fibrils in the softer articular cartilage and induces collagenase
accessibility to these fibrils (Pratta et al., 2003). In early OA, a decrease in hyaluronan
content, diminution of proteoglycan aggregates and monomers, and decreased aggregation
of the monomers have been reported (McDevitt & Muir, 1976; Sweet et al., 1977; Vasan,
1980; Tyler, 1985; Martel-Pelletier et al., 1988; Rizkalla et al., 1991). 
The levels of mRNA for cartilage matrix components, especially type II collagen, are high
in growing and immature cartilage, but adult cartilage has a very limited capacity for
matrix synthesis (Poole, 2003a). However, in early OA, there are distinct attempts at carti-
lage repair in adult cartilage (Eyre et al., 1980; Sandy et al., 1984). The transcriptional
factor Sox9 is required for transcriptional upregulation of Col21 gene (Lefebvre et al.,
1997). Elevated synthesis of type II collagen and proteoglycans is associated with attempt-
ed cartilage repair during early OA in humans (Poole, 1993; Aigner et al., 1999).  Elevated
expression of type II collagen, but not aggrecan core protein mRNA, has been shown in
OA in horses (Fehr et al., 2000). 
2.4. Rheumatoid arthritis 
Rheumatoid arthritis is an autoimmune disease accompanied by signs of systemic distur-
bance. The autoimmune phenomena in humans are probably genetically determined
(Winchester et al., 1992). To establish a diagnosis of RA, the production of "rheumatoid
factors" should be established (Harris, 1990). However, rheumatoid factors can also be
found in other conditions such as viral and liver diseases (Grassi et al., 1998b). Rheuma-
toid factors are antibodies which react with altered host immunoglobulins to form
immunocomplexes (Paget & Gibofsky, 1979). The resultant immune complexes are
deposited on the synovium and articular cartilage, initiating inflammatory and degradative
processes (Paget & Gibofsky, 1979; Sumi et al., 1986). In rheumatoid patients, subacute or
chronic nonsuppurative joint inflammation usually affects three or more joints (Harris,
1990). Morning stiffness in and around the joints is a sign typical of RA (Grassi et al.,
1998a). Evidence suggests that transcription factor NF-KB plays a critical role in the acti-
vation and proliferation of synoviocytes (Yamanishi & Firestein, 2001). Histological
changes include hyperplasia of synoviocytes and an inflammatory cellular infiltrate
composed mainly of mononuclear cells. Numerous villi and swollen masses of redundant
synovial tissue fill the joint. Inflammation often leads to formation of pannus, a fibrovascular
granulation tissue arising from the perichondral synovial membrane (Kobayashi & Ziff,
1975). The pannus is firmly attached to the articular cartilage, and degradation by proteolytic
enzymes from monocytes and fibroblasts eventually leads to destruction of the articular carti-
lage (Harris et al., 1977). Articular cartilage degeneration also occurs in the deep layers near
the bone-cartilage interface (Dodge & Poole, 1989). Subchondral bone inflammation leads to
erosive bone changes characteristic of RA (Harris, 1990). In animals, RA has been described
in dogs, but there are no reported cases in horses (Coughlan et al., 1998; Bertone, 2002). 
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3. Treatment of synovitis in horses 
The basic treatment of primary synovitis entails rest, limited motion, and physical therapy.
A full racing schedule often limits this option in fit horses. Intra-articular therapy is an
alternative, common treatment for synovitis. Certainly the most widely used intra-articular
therapy for exercise-associated articular pain is corticosteroids. Being the most potent
anti-inflammatory agents available, they are considered beneficial in treating the synovi-
tis-capsulitis entity of traumatic arthritis in the horse (Trotter, 1996). The blockage of
phospholipase A2 leads to reduced formation of eicosanoid derivatives (Higgins & Lees,
1984). Corticosteroids eliminate pain, decrease joint swelling, and stabilize cell
membranes, thus preventing recruitment of inflammatory mediators, destructive enzymes,
and inflammatory cells into the joint (Trotter, 1996). However, their use, particularly
repeated use, remains controversial in equine athletes due to their inhibitory effects on
chondrocyte metabolism (Dechant et al., 2003). 
Medical application of hyaluronan, namely sodium hyaluronate (NaHA), is successfully
used for treatment of OA in humans and horses. Suppression of PGE2 production by the
synoviocytes, decreased vascular permeability, and increased synovial fluid hyaluronan
content are offered as possible mechanisms for the therapeutic effects of NaHA (Asari et
al., 1998). Symptomatic improvement, i.e. reduced pain and improved joint mobility, can
be dramatic (Gotoh et al., 1993). In vitro, NaHA stimulates proteoglycan synthesis by
equine chondrocytes (Frean et al., 1999). Cartilage-sparing effects by high molecular
weight NaHA were reported after partial menisectomy in rabbits (Kikuchi et al., 1996). In
the horse, NaHA is most effective in treating acute synovitis-capsulitis rather than more
advanced disease (Caron & Genovese, 2003). Systemic administration of NaHA was
effective in improving clinical signs associated with joint disease caused by osteochondral
fragmentation (Kawcak et al., 1997). 
Suggested mechanisms for the favorable effects of polysulfated glycosaminoglycans
(PSGAGs) include chondroprotection and inhibition of PGE2 synthesis (Altman et al.,
1989; Frean & Lees, 2000). PSGAGs are principally made up of chondroitin sulfate. Carti-
lage-sparing effects are attributed to the inhibition of degradative enzymes (Altman et al.,
1989). There is in vitro proof that aggrecanase action is inhibited by another chondropro-
tective drug, pentosan polysulfate (Ghosh, 1999). Clinical experience suggests that
pentosan polysulfate is effective in reducing lameness in racehorses with OA (Little &
Ghosh, 1996).
Systemic administration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been used
to stop inflammatory processes and enable increased weight-bearing. Their main effect is
inhibition of the prostaglandin pathway of arachidonic acid metabolism via the blockage
of induced cyclo-oxygenase (Vane, 1976). However, the effects of COX inhibitors on
cartilage structure are unknown (Pelletier et al., 2001). Most NSAIDs are ineffective in
inhibiting IL-1-induced cartilage degradation (Rainsford, 1985). In addition, they may
have inhibitory effects on chondrocyte metabolism (Fujii et al., 1989).
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4. Surgical synovectomy
With the development of instrumentation and surgical techniques, arthroscopy has
surpassed arthrotomy in diagnosis and management of joint diseases. Advanced arthro-
scopic techniques have enabled removal of 95% of diseased synovial tissue in the human
rheumatoid knee joint, providing long-term relief of pain and swelling as well as improve-
ment in joint function (Rosenberg et al., 1996). However, arthroscopic synovectomy does
not halt progression of RA (Gibbons et al., 2002; Roch-Bras et al., 2002). Magnetic reso-
nance imaging (MRI) signs of recurrent synovitis may be present within two months of
surgical synovectomy (Ostergaard et al., 2001). 
Indications and potential benefits of surgical synovectomy in horses have not been proper-
ly determined (Caron & Genovese, 2003).  A retrospective study of racehorses claimed
better racing results after surgical synovectomy (Roneus et al., 1997). However, the phys-
iologic significance of the slow regenerative capacity of equine synovium is not known.
Avillous appearance of the synovium and poor regeneration of synovial lining were
reported three months after surgical synovectomy in horses (Theoret et al., 1996; Doyle-
Jones et al., 2002). 
5. Chemical synovectomy
Chemical synovectomy in humans has been attempted with the aid of various products
such as osmic acid, the alkylating agents nitrogen mustard and thio-tepa, methotrexate,
and antibiotics (Cruz-Esteban & Wilke, 1995). The risk of chondrocyte necrosis and
systemic toxicity has decreased the popularity of chemical synovectomy (Niculescu et al.,
1976; Molho et al., 1999). However, osmic acid and rifampicin are still occasionally used
to treat chronic hemophilic synovitis (Molho et al., 1999; Rodriguez-Merchan & Wiedel,
2001).
6. Radiation synovectomy
6.1. Radionuclides 
Radiation synovectomy has been used in human medicine for over 50 years to treat RA
(Fellinger & Schmid, 1952). Many radionuclides have been employed for synovectomy,
including holmium-166 (166Ho, max 1.8 MeV), dysprosium-165 (165Dy, max 1.3 MeV),
yttrium-90 (90Y, max 2.2 MeV), gold-198 (198Au, max 1 MeV), phosphorus-32 (32P, max
1.7 MeV), rhenium-186 (186Re, max 1.1 MeV), and erbium-169 (169Er, max 0.3 MeV).
They all emit primarily  radiation; and 198Au, 166Ho, 165Dy, and 186Re also emit  radia-
tion. The radionuclides most frequently used are 90Y and 198Au (Zuckerman et al., 1987).
However, 198Au is being abandoned in favor of the pure  emitter 90Y (Clunie & Ell,
1995). The ideal radionuclide is a  emitter with low  emissions and a maximum tissue
21
penetrance of less than 10 mm. It should have sufficient MeV for effective synovectomy
and short half-life to minimize extra-articular leakage (Johnson & Yanch, 1991). Further-
more, it should be chemically pure, nontoxic, and economically viable (Zuckerman et al.,
1987). The use of different radionuclides varies depending on the size of the joint and the
energy of the radionuclide. 90Y is suitable for the knee and joints with a greatly thickened
synovium because of its deep tissue penetration (mean = 3.8 mm, max = 11 mm) (Johnson
& Yanch, 1991). For intermediate-sized joints, 186Re has been recommended, and for the
smallest joints 169Er is best suited (Clunie & Fischer, 2003). Short physical half-lives are
desirable since leakage of radioactivity from the joint takes time, and nuclei that decay
before leaking do not subject the patient to unnecessary extra-articular radiation (Johnson
et al., 1995). The half-life of 165D is very short (0.1 day) which makes it difficult to use for
clinical purposes due to the requirement of fast transportation times from manufacturer to
patient. From a clinical viewpoint, 166Ho is much more practical for widespread use
because of its longer half-life (1.1 days) (Hosain et al., 1990). 
6.2. Carriers for radionuclides 
If an unconjugated radionuclide were to be injected directly into a joint, it would rapidly
diffuse out due to its small molecular size. This would increase radiation to normal organs.
Therefore, radionuclides must be attached to nondiffusible particles. Properties of an ideal
particle include biodegradability, good synovial uptake, stable preparation in vitro, little or
no leakage from the joint, quick, easy, and reproducible preparation, and no toxic or aller-
genic properties (Sledge et al., 1977). Typically, radionuclides are attached to colloids or
larger aggregates (Srivastava & Dadachova, 2001). 
The disadvantage of using inorganic colloid particles is significant extra-articular leakage
(Sledge et al., 1977; Noble et al., 1983; Johnson & Yanch, 1991). The leakage can be
reduced if the patient stays in bed for few days or the leg is splinted after injection (Oka et
al., 1971; Clunie & Fischer, 2003). Of particular concern is transport of particles through
lymphatics to regional lymph nodes, which causes a high radiation dose to circulating
lymphocytes. The small particle size of 198Au results in high extra-articular leakage and
chromosome damage, and hence, radiation risk to normal organs (Virkkunen et al., 1967).
A significantly elevated number of chromosome anomalies was also observed after treat-
ment with 90Y (de la Chapelle et al., 1972). Lymphocyte damage might increase the risk
for a carcinogenic effect, i.e. development of leukemia (Stevenson et al., 1973). However,
a long-term study found no evidence of increased risk for cancer after 90Y synovectomy of
the knee joint (Vuorela et al., 2003). Beta emitters combined with tin-colloids can prevent
leakage by forming particles of appropriate size (Lee et al., 2003a). 
The problem of leakage of radioactivity from the joint can be diminished by using larger
aggregates (Noble et al., 1983). Particles of 1-20 µm are ideally suited for RSYN; they are
small enough to be phagocytosed by synoviocytes but large enough to be retained in the
joint (Hnatowich et al., 1978; Noble et al., 1983). The radionuclide 166Ho is coupled with
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ferric hydroxide macroaggregate particles (FHMA, size 3-8 m), which are a hundred
times larger than traditional colloids (Ingrand, 1973; Penttilä et al., 1998). The affinity of
the synovium for FHMA is excellent since iron in FHMA is taken up well by the synovio-
cytes (Ball et al., 1964). 
6.3. Dose absorbed by the synovium
Precise calculations of the dose absorbed by the inflamed synovium are difficult for many
reasons. Estimation of the thickness of the synovial membrane and villous formation are,
for instance, problematic. Some authors have attempted to calculate the absorbed dose by
analyzing simple schemes of distribution (Ingrand, 1973). However, the estimated dose
absorbed by the synovium was consistently inaccurate as a result of the simplified
assumptions utilized in calculations (Johnson & Yanch, 1991). 
Most published studies employ absorbed dose profiles from a mathematical model using
joint phantoms to determine an appropriate radionuclide and to estimate the proper dose
(Deutsch et al., 1993). Mathematical calculations of  particle dosimetry assume uniform
intra-articular distribution of radiopharmaceuticals (Johnson & Yanch, 1991). These
profiles reveal the dose absorbed by major components of the arthritic synovial joint as a
function of penetration distance (Johnson & Yanch, 1991). The profiles can be used to
select the proper radionuclide for individual joints and specific synovium conditions. If
the volume of synovial tissue is known, advanced absorbed dose factors versus depth
profiles help to evaluate dose rates even more accurately (Johnson et al., 1995). 
6.4. Experimental studies of intra-articular effects
In horses, RSYN with samarium-153 hydroxyapatite microspheres (153Sm M) has resulted
in painful synovitis (Yarbrough et al., 2000a). Overt lameness improved within a few
days, but effusion and edema persisted for two weeks. Joints studied 14 days after RSYN
showed focal necrosis of the synovial intima. The pattern of synovial destruction was
similar between low- and high-dose joints, but joints injected with the high dose showed
more complete removal of the synovial lining (Yarbrough et al., 2000a). While treatment
with 153Sm M could not suppress synovial effusion associated with joint disease caused by
osteochondral fragments, 153Sm M itself did not harm the articular cartilage (Yarbrough et
al., 2000a, 2000b).
Several studies have shown good and uniform uptake of 90Y colloid by the synovium
(Webb et al., 1969; Isomäki et al., 1972; Ingrand, 1973). In histological examination, fibri-
noid necrosis, regression of synovial villi, reduction of cellular infiltrations, extensive
fibrosis, and occlusion and sclerosis of smaller synovial vessels and capillaries have been
observed after 90Y treatment (Pavelka et al., 1975; Meier-Ruge et al., 1976; Myers et al.,
1989). The severity of synovial abnormalities has varied between different individuals and
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within individual joints (Pavelka et al., 1975; Sledge et al., 1987; Myers et al., 1989). In
rabbits, full regeneration of the synovial membrane has occurred within 6-9 weeks follow-
ing RSYN (Mitchell & Cruess, 1967a; Pavelka et al., 1975; Gomar & Arquelles, 1978). 
One of the concerns regarding RSYN is its potential to cause cartilage damage. In addi-
tion to direct radiation damage, synovectomy has been suggested to result in some
degree of enzymatic degradation of cartilage, which continues until synovial regenera-
tion is complete (Mitchell & Cruess, 1967b). Mitotic activity of chondrocytes (Ander-
son, 1977; Stockwell & Meachim, 1979) and a higher rate of cartilage matrix synthesis
in immature animals compared with adult animals (Salminen et al., 2001) might make
young articular cartilage susceptible to irradiation. Suggested radiation-induced injuries
include chondrocyte necrosis, swollen chondrocytes, and pycnotic, hypertrophic, and
irregular grouping of cartilage cells (Meier-Ruge et al., 1976; Ubios et al., 1978;
Kerschbaumer et al., 1979). 
An antigen-induced arthritis (AIA) model in rabbits is typically exploited when screening
potential synovectomy agents for treatment of RA (Deutsch et al., 1993). When progres-
sion of AIA was followed, beneficial effects of 90Y treatment outweighed the harmful
effects of radiation (Meier-Ruge et al., 1976). The beneficial effects correlated with reduc-
tion of the inflamed synovium and preservation of articular cartilage (Meier-Ruge et al.,
1976).
6.5. Clinical use in man
6.5.1. Rheumatoid arthritis 
The primary treatment for RA consists of medical treatments aimed at controlling synovial
inflammation. Usually RA can be satisfactorily controlled with disease-modifying
antirheumatic drugs, corticosteroids, or NSAIDs (Goldbach-Mansky & Lipsky, 2003;
Mullan & Bresnihan, 2003). The criteria for RSYN include persistent synovitis which has
not responded to multiple intra-articular injections of long-acting corticosteroids (Jones,
1993; Rosenberg et al., 1996; Clunie & Fischer, 2003). Therapeutic interventions need to
be implemented before the joints have undergone severe rheumatic damage (Harris, 1990).
Theoretically, progression of joint damage might be inhibited by RSYN  (Gobel et al.,
1997); however, there is little or no proof that radiopharmaceuticals do more than alleviate
symptoms (Deutsch et al., 1993).
Assessment of therapeutic effects in clinical trials has been based upon improvements in
clinical parameters based primarily upon the physical examination. These parameters
include range of joint motion, presence and size of joint effusion, crepitus with motion,
circumference of the knee at midpatella, local pain, and patient satisfaction (Deutsch et al.,
1993). The problem in assessing clinical response lies in the fluctuating history of rheuma-
toid joint effusions and difficulties in quantifying clinical signs. 
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Scintigraphy and color ultrasound examination of the rheumatoid synovium are useful
imaging procedures for objective assessment of synovial inflammation (Pons et al., 1996;
Terslev et al., 2003). MRI of the knee is the preferred technique to assess thickness of the
synovium (Alonso-Ruiz et al., 1998; Pirich et al., 1999; Lee et al., 2003b). MRI studies
suggest effective long-term (>1 year) suppression of synovial lining hyperplasia after
RSYN (Alonso-Ruiz et al., 1998; Pirich et al., 1999; Lee et al., 2003b).
Preliminary results of RSYN with 166Ho FHMA suggest that 71% of patients with RA
have partial or complete resolution of clinical signs after synovectomy (Ofluoglu et al.,
2002). Clinical trials report a 60-70% success rate after 90Y synovectomy (Doyle et al.,
1977; Sledge et al., 1986), but the results vary depending on the joint involved (Jahangier
et al., 2001). However, most RSYN studies have been poorly designed; the studies have
not been blinded and have had insufficient sample sizes (Jones, 1993). A critical reanalysis
based on randomized controlled trials indicates only a marginal effect of 90Y (Jones, 1993;
Heuft-Dorenbosch et al., 2000). In a double-blinded randomized trial, effects of 153Sm M
treatment with cortisone did not differ from cortisone treatment alone one year after treatment
(O'Duffy et al., 1999). These disappointing findings might be associated with insufficient
action of the radionuclide on the diseased synovium (Guaydier-Souquieres et al., 1989).
6.5.2. Other arthritides
Hemophilia is a sex-linked inherited disorder characterized by protracted hemorrhages in
various sites including the joints. The underlying defect in the hemophilic patient is abnor-
mally slow coagulation of the blood. Repeated episodes of bleeding lead to chronic
synovitis, proliferation of the synovial lining, and formation of villous projections.
Inflammation is seen by the presence of neutrophils, and later, by macrophages, lympho-
cytes, and plasma cells infiltrating the subintimal tissues. Obvious benefits have made
RSYN a popular treatment for chronic hemarthrosis in hemophilic human patients (Alon-
so-Ruiz et al., 1998; Pirich et al., 1999; Rodriguez-Merchan & Wiedel, 2001).
Pigmented villous overgrowth and hemarthrosis are typical of pigmented villonodular
synovitis in man. The etiology of villonodular synovitis is unknown, but the crucial
change is massive growth of synovium inside the joint composed of lipid- and hemo-
siderin-laden cells in the subintimal tissue (Ghadially, 1983). Articular cartilage eventual-
ly suffers degeneration and joint destruction follows. In the initial trials, only 40% of clin-
ical patients benefited from RSYN (Koptan et al., 1974). Better results were reported with
combination therapy of surgical debulking and RSYN (Kat et al., 2000).  
6.5.3. Side-effects
Reactive synovitis is a frequent sequela of RSYN, and whenever possible, simultaneous
corticosteroid injection is recommended to decrease synovial flare (Lee et al., 2003a).
25
Inappropriate selection of a radionuclide has resulted in skin necrosis in finger joints
(Gumpel, 1978). Flushing of the needle is advised to prevent needle tract necrosis
(Menkes, 1979). Radiopharmaceutical allergy and septic arthritis are rare complications of
RSYN (Clunie & Fischer, 2003).
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AIMS OF THE STUDY
The aims of this study were as follows: 
(i) to determine the effects of experimental 166Ho FHMA treatment  on the synovium of
rabbits and horses (I, III),
(ii) to determine the distribution of radioactivity and risk of leakage after experimental
166Ho FHMA injection (I, III),
(iii) to determine the effects of experimental 166Ho FHMA treatment on the articular 
cartilage of rabbits and horses (II, IV).
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MATERIALS AND METHODS
1. Holmium-166 ferric hydroxide macroaggregate
166Ho is a product of the neutron activation of 165Ho and is predominantly a  emitter
(max1.8 MeV) with radiotherapeutic properties appropriate for therapy. It also emits 
radiation (81 keV, 6%) detectable at scintillation imaging. In these studies, we used 166Ho
FHMA, a sterile and isotonic combination of 166Ho and macroaggregate FHMA. Analysis
of particle size distribution showed that 75% of particles were between 3 m and 20 m in
diameter, and no particles were smaller than 0.2 m. 166Ho FHMA was prepared by MAP
Medical Technologies OY (Tikkakoski, Finland).
2. Animals and study protocol 
2.1. Rabbits
Studies included 59 growing (n=29, mean age 3.7 months, range 106-122 days, mean
weight 2.4 kg) and mature (n=30, mean age 1 year 3 months, range 446-519 days, mean
weight 5 kg) New Zealand white rabbits. The rabbits were purchased from the National
Laboratory Animal Center (Kuopio, Finland). During the studies rabbits were housed in
individual stainless steel cages. Fifty-one rabbits were used for analysis of synovium,
synovial fluid, and articular cartilage (Table 1). A volume of 0.4 ml of 166Ho FHMA was
injected into one knee. The contralateral control knee was injected with 0.4 ml of nonra-
dioactive 165Ho FHMA. 166Ho FHMA injections were given using an anterior subpatellar
approach. The mean dose of 166Ho FHMA in mature rabbits was 121 MBq and in young
rabbits 75 MBq (I, II). For the autoradiography study, eight mature rabbits were sacrificed
1-5 days following 166Ho FHMA injections. 166Ho FHMA was injected into one knee joint
as described above. The mean dose was 71 MBq/joint (I).  
Table 1. Number of rabbits studied after 166Ho FHMA injections.
Young rabbits Old rabbits 
(n=29; av. age 3.5 months) (n=22; av. age 15 months)
Group 4 days a 2 months 1 year 4 days 2 months 1 year
Treated 8 9 9 6 7 7
NC 1 1 1 1b 1b 1
NC, Not treated.
a Time-point that rabbits were studied after 166Ho FHMA injections.
b These groups of old rabbits shared an agematched negative control animal.
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2.2. Horses
Six adult mixed-breed horses (all mares, mean age 9 years, range 6-14 years, mean weight
475 kg, range 444-495 kg) were used. Horses had been raised and trained on private farms
before being sold to the University of Helsinki. Horses had no signs of joint illness based
on physical examination and had normal morphology based on radiographs of metacar-
pophalangeal (MCP) and metatarsophalangeal (MTP) joints. Radiation synovectomy of
one of the fetlock joints was performed using 166Ho FHMA, and the opposite control joint
was injected with nonradioactive 165Ho FHMA. Injections were performed under aseptic
conditions through the lateral collateral sesamoidean ligament with the joint flexed. Injec-
tions into the MCP joints were performed 2 months and into the MTP joints 5 days before
the animals were sacrificed (Figure 1). During the experiment the horses were kept in box
stalls or paddocks. One control MTP joint was discarded from the study due to a wound
infection after arthroscopy that required intra-articular NaCl flushing. The doses in horses
were 688.2 MBq, 1006.4 MBq, 1154.4 MBq, 962 MBq, 1147 MBq, 962 MBq, 1050.8
MBq, 958.3 MBq, 999 MBq, 1069.3 MBq, 1043.4 MBq, and 958.3 MBq (mean 1000
MBq). Injected activity was determined by assaying the amount of activity in the syringe
before and after injection in a well counter (Isaocal II, Vinten, UK), which was calibrated
for 166Ho. The dose was extrapolated from a preliminary human study (Ofluoglu et al.,
2002). Using the dosimetric calculations, a target dose of 1000 MBq yields a dose of 212
Gy to the equine joint (Johnson & Yanch, 1991). The study protocols were approved by the
Animal Care and Use Committee of the University of Helsinki.
MCP MCP MTP MTP MCP/MTP
arthroscopy 166Ho FHMA arthroscopy 166Ho FHMA arthroscopy
5 weeks                      3 weeks                          5 weeks                         5 days
Synovial fluid collection at Scintigraphy daily
5 days (MCP) after (MTP)
166Ho FHMA
3. Clinical signs after RSYN (I, III)
Rabbits were inspected daily for any signs of discomfort. Horses were examined daily for
signs of lameness at walk, and the limbs were inspected closely for signs of edema and
joint effusion after 166Ho FHMA treatment. Lameness at walk was evaluated daily for 5
days after 166Ho FHMA treatment. Eight weeks after 166Ho FHMA treatment, lameness at
trot was evaluated and scored (Swanson, 1984). 
Synovial  fluid collec-
tion at
5 days (MTP) and 
2 months (MCP) 
after 166Ho FHMA;
samples for histology; 
termination of  the
experimentFigure 1. Experimental protocol for horses. 
▲ ▲▲▲▲
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4. Autoradiography of rabbits (I)
For the whole knee autoradiography study, 5 rabbits were sacrificed 24 hours apart (1-5
days) after 166Ho FHMA. The dorsal joint capsules were studied 1, 2, and 3 days after 166Ho
FHMA injection. A detailed description of the autoradiography method is given in Study I.   
5. Scintigraphy of horses (III)
The 166Ho FHMA-treated MTP joints were examined daily for 5 days postinjection with
scintigraphy. Static, straight lateral, 60-second images were acquired using a large-field-
of-view gamma camera with 256 X 256 matrix size and a low-energy parallel-hole high-
resolution collimator. Before image acquisition, the camera was calibrated for the  radia-
tion energy of 166Ho (81 KeV) with a 20% window. Count rates were recorded and hand-
drawn regions of interests were drawn around the proximal plantar joint pouch and the rest
of the joint area to measure relative distribution of radioactivity in these regions.
6. Arthroscopy of horses (III, IV)
Arthroscopic examinations of horses were performed 5 weeks before the 166Ho FHMA
injections and were repeated immediately before the experiment was terminated (Figure
1). With arthroscopy, soft-tissue changes were evaluated (III) and stiffness data were
obtained for the condylar surface and the sagittal ridge on the medial side of the dorsal
joint area from treated and control joints (IV) (Figure 2A). Compressive testing of articu-
lar cartilage was performed with an arthroscopic indentation instrument validated for stiff-
ness measurements of thin articular cartilage (Artscan 1000, Artscan Oy, Helsinki, Finland)
(Lyyra-Laitinen et al., 1999). The contact plate was modified, i.e. elevated and reduced in
size, to enable measurements of small cartilage areas using a pressing force of 7 N. 
Figure 2. A schematic presentation of the sampling sites in equine and lapine joints. Three slices (black bars) of 2
mm in thickness were cut for morphometric and biochemical studies. (A) Two cartilage areas on the dorsal joint
surface of horses (spots with stripes) were used for biomechanical analyses. Cartilage was harvested from the
dorsal condylar surface (area inside the broken lines) for Northern blot. (B) The thick broken line indicates where
the lapine condyles were cut for mRNA analysis of cartilage-specific genes
30
7. Histopathological study of the synovium (I, III)
Synovium samples were collected from the dorsal aspect of the knee joint of mature
rabbits (4 days, 2 months, and 1 year after RSYN) and from the midline of the dorsal and
proximal palmar and proximal plantar joint pouches of horses (5 days and 2 months after
RSYN). For histological examination, samples were fixed in 4% formaldehyde in phos-
phate-buffered saline, embedded in paraffin wax, sectioned, and stained with hematoxylin
and eosin (HE). Ferric iron in the synovial tissue was demonstrated by Pearls' Prussian
Blue staining and calcification using the von Kossa silver method. 
8. Synovial fluid (I, III, IV)
Synovial fluid wash samples of mature rabbits were studied 4 days and 2 months after
166Ho FHMA injections. Joint fluid samples were analyzed for total white blood cell count
and total protein concentration. For total protein concentration, the samples were
centrifuged at 5200g for 5 mintes, and the cell-free supernatants were collected. The total
protein concentration was determined colorimetrically by the biuret method.
Synovial fluid samples from horses were collected 5 days and 2 months (only MCP joints)
after RSYN (Figure 1). The synovial fluid was diluted 1:10 with 0.9% NaCl before analy-
sis of total white blood cell count in a Bürker chamber. For total protein and GAG levels,
samples were centrifuged at 8000g for 10 minutes, and the supernatants were collected.
For analyses of GAGs, samples were digested with papain for 2-3 hours at 60oC. The
concentration of GAGs was measured in a 1.9-dimethylmethylene blue binding assay
(Farndale et al., 1986). Analysis of residual radioactivity in synovial fluid was performed
by liquid scintillation counting (Winspectral™, Wallac, Turku, Finland) using a water-
soluble scintillation cocktail (Optiphase Hisafe III, Wallac, Turku, Finland). The results
were compared with those of known low-activity 166Ho FHMA standards.
9. Articular  cartilage analyses (II, IV)  
9.1. Metabolic labeling of articular cartilage
Three slices of articular cartilage with subchondral bone were cut from the medial condy-
lar surface of the metatarsal III and metacarpal III bones of horses (Figure 2A) and from
the distal femur of rabbits (Figure 2B). Cartilage samples from horses were collected 5
days and 2 months after RSYN, and from rabbits 4 days, 2 months, and 1 year after
RSYN. One slice was taken for histology, quantitative autoradiography, and densitometric
analyses of GAGs, another one for total sulfate incorporation and uronic acid analyses,
and the third for electrophoretic analysis of proteoglycans. All slices were metabolically
labeled with sulfur-35 (35S) sulfate. After labeling, the slices were washed to separate most
of the unincorporated 35S sulfate precursor. 
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9.2. Cartilage histology and assessment of the superficial collagen network
Specimens for histology were fixed in 4% formaldehyde at 4°C for 20 hours, followed by
decalcification in buffered 10% EDTA and 4% formaldehyde for 12 days at room temper-
ature, dehydration with alcohol, and embedding in Paraplast Plus wax.  Specimens were
cut into 3-m-thick sections for safranin-O staining, and 5-m-thick sections for HE
staining and subsequent histologic assessment. In rabbits, quantitative polarized light
microscopic analyses were performed to assess the superficial collagen network (II). In
horses, degenerative changes were evaluated from the HE-stained sections according to
the following scale: 0 = normal cartilage, 1 = fibrillation, 2 = horizontal fibrillation, 3 =
vertical fibrillation, and 4 = erosion of cartilage (IV).
9.3. Digital densitometry of glycosaminoglycans and thickness measurement of
uncalcified cartilage
Densitometric determination of GAG concentration in safranin-O-stained sections was
carried out as described previously (Kiviranta et al., 1985; Panula et al., 1998; Suominen
et al., 2001). The measured area spanned from the cartilage surface to the tidemark. The
thickness of the uncalcified articular cartilage was measured and divided into 12 fractions,
each corresponding to 1/12 of the total thickness of the cartilage and with a constant width
of 620 m. The two most superficial fractions represented the superficial, the next five
fractions the intermediate, and the deepest five fractions the deep zone of the articular
cartilage. The results were calculated as the mean area-integrated optical density propor-
tional to 1 m2 in each zone.
9.4. Uronic acid content
Proteoglycans were quantified as uronic acid. The GAG content of cartilage was calculat-
ed as micrograms of uronic acid per milligram of wet weight, as measured with the m-
hydroxydiphenyl method (Blumenkrantz & Asboe-Hansen, 1973).
9.5. Electrophoretic analysis of proteoglycans 
Cartilage was dissected with a surgical knife from the underlying bone and finely diced
with a scalpel blade (unnecessary for rabbit cartilage). After determination of wet weight,
proteoglycans were extracted with 500 l of 4 M guanidinium hydrochloride in 50 mM
sodium acetate (pH 5.8), containing inhibitors of bacterial growth and proteases (Lammi
et al., 1993). Extraction was continued at 4oC for 24 hours. After the samples were precip-
itated in ethanol, proteoglycan monomers were characterized by sodium dodecyl sulfate
(SDS) agarose gel electrophoresis (Säämänen et al., 1990).  The gels were stained with
toluidine blue, dried and scanned for densitometry, and exposed to x-ray films for two
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weeks. The scanned film and gel densities were analyzed with image analysis software
(IP-Lab, Scananalytics, Fairfax, VA, USA) (Lammi et al., 1993).
9.6. Autoradiographic analysis of cartilage zones
For autoradiography, the tissue blocks containing articular cartilage and underlying bone
were prepared as described earlier (Parkkinen et al., 1990; Lammi et al., 1993; Suominen
et al., 2001), with the exception that no background staining was used. Microscopic analy-
sis of grain area fraction was performed using image analysis. Each microscopic view was
divided into ten fields from cartilage surface to the tidemark. The two most superficial
fractions represented the superficial zone, the four consecutive fields the intermediate
zone, and the four deepest fractions the deep zone. The results are presented as the average
grain fraction percentage of the total tissue volume. 
9.7. Total incorporation of  sulfur-35 sulfate
After metabolic labeling, cartilage was dissected free from underlying bone, weighed,
and digested overnight at 60oC with 0.05% proteinase K and 10 mM EDTA. Unincor-
porated sulfate precursors were removed by gel filtration. Radioactivity in each sample
was determined by liquid scintillation counting to study the metabolic activity of the
chondrocytes.
9.8. Northern hybridizations 
Articular cartilage samples from horses were harvested with a razor blade for pulveriza-
tion of the tissue (Figure 2A). Both femoral condyles of rabbits were cut for total RNA
extraction (Figure 2B). For extraction of total RNA, modification of the guanidinium
isothiocyanate method was used (Chirgwin et al., 1979). The samples were frozen, pulver-
ized under liquid nitrogen, homogenized in 4 M guanidinium isothiocyanate, and sedi-
mented through 5.7 M cesium chloride. For Northern analysis, 10-g aliquots of total
RNA were denatured with glyoxal and dimethyl sulfoxide, run on 0.75% agarose gels, and
transferred overnight with 20 X SSC onto Pall Biodyne membranes, after which the filters
were incubated at 80oC for 2 hours as recommended by the supplier. For Northern
hybridizations, cDNA clones were labeled to specific activities of approximately 1x109
cpm/g using a Random Primed DNA labeling Kit (Boehringer Mannheim, Germany)
and 32P dCTP. The hybridizations were performed at 42oC in 50% formamide, 1 M NaCl,
1% SDS, 10% dextran sulfate, 5 x Denhardt's, and 100 g/ml sonicated calf thymus DNA.
After high-stringency washes, the bound probes were detected and quantified on a Molec-
ular Imager phosphor imager (BioRad, Hercules, CA, USA) and the mRNA signals were
corrected for variations in the 28S rRNA levels determined by hybridization. The probes
used in Northern hybridizations are listed in Table 2. A cDNA clone for equine type II
33
collagen mRNA was constructed using the reverse transcription polymerase chain reaction
(RT-PCR) technique and total RNA from the equine articular cartilage as a template
(detailed description of the RT-PCR technique is given in Study IV). 
Table 2. List of cDNA clones used as hybridization probes.
mRNA Probe Reference
Pro1(II) collagen pECol21-1 IV
Pro1(II) collagen pKCol21-1 Metsäranta et al. 1996
Aggrecan pHAgg-1 Glumoff et al. 1994 
Sox9 pHSox9 Lefebre et al. 1998
28S ribosomal RNA 28S Iruela-Arispe et al. 1991
10. Statistical analyses
The statistical significance between treated and control groups was analyzed by Wilcoxon's
matched-pairs signed-rank test. 
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RESULTS
1. Clinical signs after RSYN (I, III)
The rabbits showed no signs of discomfort during the experiment. Radiation synovectomy
caused severe pain in two horses after treatment of MCP joints. These horses were treated
with butorphanol tartrate (Torbugesic®Vet, Fort Dodge Animal Health, Girona, Spain) for
nonweight-bearing lameness. After 166Ho FHMA treatment of MTP joints, none of the
horses needed treatment for pain. All horses developed circumferential edema of the treat-
ed limb. Edema disappeared within 2 weeks, but was replaced by a painful fibrotic thick-
ening around the palmar joint pouch in 4 weeks. Edema made evaluation of effusion diffi-
cult, but 5 days after radiation synovectomy aspiration of joint fluid revealed elevated
pressure in the joint space. Eight weeks after radiation synovectomy, three horses had
forelimb lameness at trot (grade 3 lameness) and two horses had effusion of MCP joints.
Control joints showed no pain, effusion, or edema.
2. Autoradiography of rabbits (II)
During the first two days whole-knee autoradiograms of rabbits showed that most of the
radioactivity stayed in the joint space (Figure 3A). Two days after 166Ho FHMA injection,
some radioactivity was observed inside the bone near the femoral attachment of the cruciate
ligament. On the third day, much of the 166Ho FHMA had been phagocytosed by the
synoviocytes or had leaked out, i.e. radioactivity was observed between the muscles (Figure
3B). Autoradiograms on the fourth and fifth day showed low levels of radioactivity in the
joint space and uneven distribution along the synovium. Autoradiograms of the isolated
synovium samples supported uneven incorporation of 166Ho FHMA into the synovium.   
Figure 3. Anatomical sections of whole rabbit knees on cryotape with respective autoradiograms (lower panel) on
1 day (A) and 3 days (B) after intra-articular 166Ho FHMA injection. (A) Patchy distribution of radioactivity in
the joint space. (B) Radioactivity between the muscles.
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3. Scintigraphy of horses (IV) 
In horses, radioactivity was mainly distributed in the proximal plantar joint pouch (on
average 82%), and only minor amounts (18%) were detected in other parts of the joints.
However, in one MTP joint, radioactivity was more evenly distributed between the proxi-
mal plantar joint pouch (58%) and other compartments (40%). The distribution of radioac-
tivity remained the same for 5 days after radiation synovectomy. No obvious extra-articu-
lar leakage was detected between days 2 and 5.
4. Arthroscopy of horses (III) 
Arthroscopic findings were minimal in the dorsal joint pouch, and cartilage was visually
normal. The dorsal aspect of equine fetlock joints was well suited for repeated in vivo
measurements of the compressive stiffness of articular cartilage (Figure 4). Compressive
testing of articular cartilage showed no difference between reference and follow-up measure-
ments 5 days after RSYN. However, 2 months after RSYN, articular cartilage on the sagittal
ridge, but not on the condylar surface, was softer in the treated joint than in the control joint. 
Figure 4. Indentation analysis of equine articular cartilage with an arthroscopic instrument (arrowhead) and an
elevated reference plate (arrow). Perioperative view (A) and arthroscopic view (B).
5. Histopathological study of the synovium (I, III) 
In rabbits, RSYN caused partial necrosis of the synovial membrane (Figure 5A). In
nonnecrotic areas, the synovial lining was 1-2 cells thick, with some polymorphonuclear
cells in the subsynovial tissue. In control knees, 165Ho FHMA induced pronounced
proliferation of synoviocytes; this was an unusual finding in 166Ho FHMA-treated knees
(Figure 5B). In the samples taken 2 months and 1 year after RSYN, regeneration of the
synovium, subintimal fibrosis, and subintimal iron deposits in both treated and control
knees were typical. 
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Figure 5. Hematoxylin- and eosin-counterstained sections of lapine synovium 4 days after intra-articular injec-
tion of 166Ho FHMA. (A) Necrotic tissue (arrows) on the synovial surface. (B) Control knee injected with nonra-
dioactive 165Ho FHMA; hyperplasia of the synovium. Bar = 50m.
In horses, histological analyses showed a normal 1- to 2-cell-layer-thick synovial
lining in the dorsal joint pouch of all radiosynovectomized joints. Synovial samples
from the plantar pouches of MTP joints of horses showed deep multifocal necrosis of
the synovium after 166Ho FHMA treatment. Mononuclear cell reaction with congested
capillaries and hemorrhage was observed in the subsynovial tissue. Iron-loaded
synoviocytes and iron debris were shown in both treated and control joints. By 2
months, large areas of necrotic tissue were still present in the plantar pouches of the
MCP joints. Furthermore, large areas of granulation tissue with capillaries, fibroplasia,
and mononuclear cell infiltration in the subsynovial tissue were evident. Overall regen-
eration of the equine synovium was poor 60 days after RSYN despite the presence of
granulation tissue. 
6. Synovial fluid (I, III, IV) 
In rabbits, 4 days after treatment with 166Ho FHMA, white blood cell counts and protein
concentration had increased significantly (p<0.05) compared with synovial fluid values
from control knees. Two months after RSYN, cell counts and protein values were no
different from those of control joints.       
In horses, synovial fluid protein concentration increased significantly (p<0.01) and
residual radioactivity was 0.5 MBq/ml in synovial fluid 5 days after RSYN.  White
blood cell counts were not significantly different from those of control joints. After 2
months, protein concentration had decreased to that of the control joints. Mean GAG
concentration was slightly higher in the synovial fluid samples from radiosynovec-
tomized joints, but this increase was not significant compared with  samples from
control joints. 
37
7. Articular cartilage analyses (II, IV)
In mature rabbits, degenerative changes occurred equally in 166Ho FHMA-treated and
control knees. In young rabbits, fibrillation of superficial cartilage layers was observed
slightly more often in 166Ho FHMA-treated knees than in control knees. The thickness of
articular cartilage, on average 505 m in mature rabbits and 388 m in growing rabbits,
was unaffected by RSYN. Digital densitometry of GAGs (Table 3) or uronic acid analyses
did not show any marked change in composition of articular cartilage; neither was the size
of proteoglycans affected by 166Ho FHMA treatment. Both incorporation analysis of tissue
samples and autoradiographic analysis of cartilage specimens showed that RSYN had no
significant effect on metabolic activity of chondrocytes. In Northern analysis, the levels
for pro-1(II) collagen mRNA were considerably higher in growing rabbits than in rabbits
over 1 year of age (Figure 6).  Slightly reduced Sox9 and aggrecan mRNA levels were seen
in treated knees of young rabbits 2 months after treatment in comparison with the
contralateral control knees (Figure 6). At the 1-year follow-up, no differences were seen in
mRNA levels between 166Ho FHMA-treated and control joints.    
Young rabbits Old rabbits
(n=7)          4 days after 166Ho FHMA (n=6)
Group Superficia Intermediate Deep zone Superficial Intermediate Deep zone
zone zone zone zone
Synovectomy 0.102 ± 0.009a 0.135 ± 0.007 0.142 ± 0.006 0.109 ± 0.011 0.155 ± 0.009 0.164 ± 0.011
Control 0.122 ± 0.009 0.150 ± 0.005 0.154 ± 0.005 0.12 ± 0.017 0.154 ± 0.018 0.172 ± 0.014
NC 0.099b 0.136 0.147 0.153 0.175 0.184
(n=8) 2 months after 166Ho FHMA (n=6)
Synovectomy 0.119 ± 0.011 0.147 ± 0.009 0.153 ± 0.009 0.127 ± 0.007 0.165 ± 0.005 0.172 ± 0.003
Control 0.128 ± 0.009 0.160 ± 0.006 0.166±0.007 0.118 ± 0.018 0.157 ± 0.014 0.174 ± 0.012
NC 0.125 0.158 0.166 0.153 0.175 0.184
(n=9) 1 year after 166Ho FHMA (n=6)
Synovectomy 0.086 ± 0.010 0.111 ± 0.008 0.121 ± 0.007 0.100 ± 0.012 0.125 ± 0.004 0.132 ± 0.003
Control 0.079 ± 0.007 0.107 ± 0.005 0.119 ± 0.003 0.090 ± 0.014 0.116 ± 0.005 0.126 ± 0.004
NC 0.091 0.109 0.110 0.083 0.104 0.111
Table 3. Digital densitometry of safranin-O-stained slides, area-integrated optical
density (OD/m2) in superficial, middle, and deep cartilage zones.
NC, Not treated.
a Mean ± SEM. bMean values of negative controls.
Data are mean ± standard error of mean (with number of paired observations in parenthesis). The two-tailed
nonparametric Wilcoxon’s matched-pairs signed-rank test was used for statistical analysis; no significant differ-
ences were found between the synovectomy and control groups.
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In horses, despite visually normal cartilage, vertical and horizontal clefts were observed in
the histological analysis of fetlock joints. The analysis showed no obvious difference in the
mean score for cartilage degeneration between treated (1.8; range 1-3) and control (2;
range 1-3) joints. Neither was there a significant difference between the mean cartilage
thickness of treated and control joints (633 m vs. 729 m). Glycosaminoglycan concen-
tration was not altered in any zone of the safranin-O-stained histological samples; nor did
uronic acid analysis indicate proteoglycan loss after intra-articular 166Ho FHMA treatment.
Migration of proteoglycan bands was not markedly affected by RSYN with 166Ho FHMA,
although a slightly decreased average size of proteoglycans was observed in the treated
MCP joints. Five days after RSYN, the 35S sulfate incorporation rate into the articular
cartilage was not affected, but at the 2-month follow-up the incorporation rate was lower in
the radiosynovectomized joints than in the control joints (5.0 ± 1.1 pmol/mg wet
weight/hour [mean ± SEM] and 1.8 ± 0.8 pmol/mg wet weight/hour, respectively). The
change was not, however, statistically significant. In the autoradiographic analysis of carti-
lage zones, 166Ho FHMA treatment had no effect on chondrocyte metabolism. Five days
after RSYN, mRNA levels for aggrecan were unchanged, but levels for pro1(II) collagen
were decreased in the radiosynovectomized joints compared with the contralateral control
joints. However, this change was not significant. At the 2-month follow-up, no differences
were seen in the mRNA levels between 166Ho FHMA-treated and control joints.
Figure 6. Expression of pro1(II) collagen, aggrecan, and Sox9 mRNAs in the articular cartilage of young rabbits.
The hybridization signals were quantified by phosphor imaging, and the values were normalized against a 28S
rRNA signal. Col2a1, pro1(II) collagen. AGG, aggrecan.
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DISCUSSION
1. General comments on the design of the experiment
Rabbits are often used to test the effects of drugs and various treatments on joints. The
most commonly used experimental animal for screening of potential radiosynovectomy
agents for human use (Deutsch et al., 1993), the rabbit was also chosen as an experimental
animal here. In addition, the horse was deemed a suitable animal since its fetlock joint is
nearly the same size as the knee joint of man. Unlike human medicine, veterinary medi-
cine has the benefit of being able to use experimental animals from species that are also
clinically relevant. However, horses are expensive and are not readily available for
research purposes. The costs can be prohibitive, especially when large numbers of animals
need to be tested over extended periods of time. 
2. Effects of 166Ho FHMA treatment on the synovium
In both species, treatment with 66Ho FHMA caused multifocal necrosis of the synovium.
Living tissue reacts to  radiation by excitation and ionization of the atoms and molecules.
Formation of free radicals along with the radiation results in cellular changes both in the
nucleus and in the cytoplasm, leading to cell death (Anderson, 1977). The severity of
observed synovial abnormalities after RSYN varied in individual rabbits, as has been
reported in previous studies (Pavelka et al., 1975; Sledge et al., 1987; Myers et al., 1989).
Necrotic synovium could only be evaluated from the knees of mature rabbits since the
synovial lining was very fragile in young rabbits. Rabbits and horses had two very
different types of synovium; rabbits have an adipose-type subintima in the knee, where-
as in the equine fetlock joint it is fibrous-type. This might have had an influence on the
severity of symptoms after RSYN. Rabbits did not show any signs of discomfort, while
some of the horses had severe lameness and all of the horses had scar tissue formation
after 166Ho FHMA treatment. The dose of 166Ho FHMA does not explain the differences
in clinical signs since rabbits received high doses of intra-articular radiation relative to
the size of the knee. 
Absence of hyperplasia in radiosynovectomized joints indicated that a variable number of
cells on the morphologically normal synovial lining had lost their ability to divide. The
exposure of rapidly dividing cells to intermediate doses of radiation results in a phenome-
non known as division delay. Typically, irradiated cells immediately cease division for a
period of time that is proportional to the absorbed dose. After this delay, the cells can
resume their normal growth patterns (Anderson, 1977). In the present study, intracellular
accumulation of iron pigment acted as a direct stimulus to proliferation of the synovium.
Effective suppression of inflammatory response using 166Ho FHMA has also been reported
in antigen-induced arthritis studies (Chinol et al., 1989, 1990b). Phagocytosing synovial
lining cells incite an inflammatory response to any foreign material appearing in the joint
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(Henderson, 1988). Here, iron pigment in the subintimal tissue appeared either as a result of
intra-articular hemorrhage or iron overload, e.g. intra-articular FHMA (Ghadially, 1983).
Both in treated and control joints, the iron pigment persisted in the subintima even 1 year
after injection.
3. Side-effects of 166Ho FHMA treatment 
Soft tissue swelling and joint effusion lasted for a maximum of 2 weeks in horses. Joint
effusion has been described as a common side-effect of RSYN (Lee et al., 2003a).
Swelling in humans usually disappears within one month following treatment (Clunie
& Fischer, 2003). Intense inflammatory reaction after RSYN has been suggested to
reflect effective ablation of the inflammatory tissues (Lee et al., 2003a). However, no
correlation was revealed between dose and clinical signs after RSYN with 153Sm M in
horses (Yarbrough et al., 2000a). Because only one target dose was chosen for this
investigation, the effect of the administered dose on clinical signs is unclear. Simulta-
neous administration of intra-articular long-acting glucocorticoids has been recom-
mended to reduce radiation-induced inflammatory reaction in humans (Clunie &
Fischer, 2003). 
Strong  emitter 166Ho penetrated deep into soft tissues, resulting in tissue necrosis, local
pain, and restricted range of motion in horses. Compared with the recommended dose for
the human knee (124 Gy/knee), 1000 MBq of 166Ho yields a radiation dose of 212
Gy/knee (Zuckerman et al., 1987; Johnson et al., 1995). This dose has been successfully
used in man without side-effects (Ofluoglu et al., 2002). Accumulated radioactivity close
to sensitive structures in the palmar aspect of fetlock joints may explain the adverse
effects in horses. A smaller dose or use of a different radionuclide might cause less harm-
ful side-effects than those observed here. Furthermore, effects on an arthritic equine joint
with a thickened synovium could be different from ours.
Increased synovial fluid protein concentration after RSYN indicated radiation-induced,
soft-tissue injury and leakage of plasma from the vasculature. The subintimal inflammato-
ry reaction apparent in horses was perhaps due to severe subintimal injury. Subintimal
and perivascular clusters of mononuclear cells were still evident 2 months after 166Ho
FHMA treatment. The slow regenerative capacity of equine synovium is in accordance
with the literature on surgical synovectomy (Theoret et al., 1996; Doyle-Jones et al.,
2002). The unaffected white blood cell counts in horses were probably species-related
since synovial fluid cell count is a poor indicator of mild joint inflammation in horses
(McIlwraith et al., 1979). 
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4. Distribution of 166Ho FHMA particles
On scintigraphy of horses, 166Ho FHMA accumulated in the palmar joint pouch with abun-
dant synovial tissue. 166Ho FHMA could not have been injected into the palmar subsyn-
ovial tissues since a careful injection technique through the lateral collateral sesamoidean
ligament was used. Increased synovial pressure might have caused compartmentalization
of 166Ho FHMA particles (Strand et al., 1995). Synovial fluid analysis for residual activity
suggested that accumulated 166Ho FHMA particles were effectively phagocytosed by the
synoviocytes. The distribution was different after 153Sm M synovectomy, in which tempo-
ral redistribution into the distal plantar recesses was reported (Yarbrough et al., 2000a).
Large-sized 153Sm M particles (20-50 m) might not be as readily absorbed by the synovi-
um as 166Ho FHMA particles (3-8 m). The uneven distribution of radioactivity was veri-
fied in arthroscopic and histopathological studies. On arthroscopy, the synovium was
largely unaffected in the dorsal aspect of the equine joints. Histopathological changes in
the palmar/plantar pouch of the fetlock joints were profound compared with those of the
dorsal recess of the joint capsule. Uneven RSYN effects concur with other experimental
studies describing multifocal necrosis of the synovium after injection with RSYN agents
(Sledge et al., 1977; Myers et al., 1989; Yarbrough et al., 2000a). In contrast to findings in
the present study, 90Y has previously been shown to be reasonably evenly distributed along
the cells of the synovial membrane in rabbits (Ingrand, 1973). Mathematical dosimetric
calculations therefore assume an even distribution of radioactivity along the synovium
(Johnson & Yanch, 1991). Although 166Ho FHMA particles were well absorbed into the
synovium, the uneven distribution renders the validity of the dosimetric calculation for
166Ho FHMA questionable (Johnson & Yanch, 1991). It is not known whether coupling of
166Ho to other carriers, such as hydroxyapatite or chitosan, would have resulted in a more
even distribution along the synovium (Song et al., 2001; Unni et al., 2002). 
5. Extra-articular leakage of radioactivity
One of the prerequisites of RSYN is that extra-articular leakage and radiation burden to
nontargeted organs be minimized. Autoradiograms of rabbit knees showed extra-articular
leakage of radioactivity on the third day after 166Ho FHMA treatment. Leakage of a radio-
pharmaceutical can be caused by a loss of intact particles from the joint, i.e. a loss of enzy-
matically degraded particles due to reduction below a critical size or a loss of the radioac-
tive label from particles positioned in the synovial pouch (Noble et al., 1983). The count
rate performance of the gamma camera was exceeded during the 2 days after 166Ho FHMA
treatment of horses, and thus high intra-articular radioactivity could not be recorded accu-
rately. However, scintigraphic analysis showed no obvious extra-articular leakage. Chinol
et al. (1990a) reported that FHMA is suitable carrier only for the short-lived radionuclides
used in synovectomy. In fact, leakage might be more a function of the short half-life of the
radionuclide than the size of the carrier (Deutsch et al., 1993). Previously, use of the same
dose of 166Ho FHMA as used in our study of young rabbits caused little extra-articular
radiation to the normal organs of  adult rabbits (Penttilä et al., 1998). 
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6. Effects of 166Ho FHMA on the articular cartilage 
In adult horses and older rabbits (>1 year old), 166Ho FHMA treatment did not affect the
biochemical composition of articular cartilage. In young rabbits, transient derangement of
the superficial collagen layer was observed, but the biochemical analysis did not support
concomitant change in the size of proteoglycan monomers or loss of proteoglycans. Active
matrix synthesis probably protected young animals from permanent cartilage damage. 
Stiffness measurements with the indentation device indicated slightly softer equine carti-
lage after RSYN. Softening of articular cartilage could be associated with loss of proteo-
glycans from the cartilage (Kempson, 1975). However, the only slight increase in synovial
fluid GAGs does not support marked structural changes after 166Ho FHMA treatment
(Alwan et al., 1991a), and biochemical analyses failed to confirm loss of proteoglycans
from the cartilage. Since the composition and morphology of equine articular cartilage
were not markedly affected by 166Ho FHMA treatment, natural degeneration is anticipated
to have caused cartilage softening. Further, repeated sequential measurements on the same
spots at various times were impossible with the small contact plate. However, it cannot be
excluded that 166Ho FHMA treatment provoked cartilage degeneration. The slightly small-
er size of aggrecan monomers in the treated joints could reflect this early degenerative
process (Vasan, 1980), although the association of reduced size of aggrecan monomers
with cartilage degeneration has not been confirmed (Brocklehurst et al., 1984). 
Upregulation of cartilage-specific genes, especially of type II collagen, has been observed
during early OA (Poole, 1993; Richardson & Dodge, 1997; Aigner et al., 1999; Fehr et al.,
2000). In dogs, 90Y synovectomy increased metabolic labeling of proteoglycans, which
has been associated with cartilage damage (Carney et al., 1984; Myers et al., 1989). In the
present investigation, there was no increased mRNA expression of type II collagen or
aggrecan in either species. Autoradiographic grain density was similar in radiosynovec-
tomized and control joints. However, the tissue analysis of chondrocyte metabolism indi-
cated slightly decreased proteoglycan synthesis in equine samples. This discrepancy might
be explained by the effect of 166Ho FHMA treatment on chondrocytes being strongest
close to the joint margins. Furthermore, large individual variation is present in the 35S
incorporation analysis of cartilage samples. 
In rabbits, autoradiographic analysis of 35S sulfate-labeled histological sections refuted
earlier observations of irradiation-induced chondrocyte injury close to the cartilage
surface (Meier-Ruge et al., 1976). The chondrocytes were more likely injured by the
chronic arthritis itself than by RSYN (Muller et al., 1975; Hembry et al., 1993). Northern
analysis suggested only transient radiation-induced derangements in matrix synthesis of
Sox9 and aggrecan mRNAs in knee cartilage of young rabbits 2 months after RSYN. The
importance of decreased mRNA expression of aggrecan remains to be determined, as no
corresponding changes were seen in proteoglycan or GAG content of the tissue. Sox9 is
one of the primary regulators of both aggrecan and the Col21 gene (Bi et al., 1999). The
reason why downregulated Sox9 mRNA did not result in decreased expression of the
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Col21 gene was not established here. In horses, the slightly lower mRNA expression of
type II collagen 5 days after 166Ho FHMA suggested cytokine-induced downregulation
was associated with radiation-induced inflammation (Richardson & Dodge, 1997).
7. General comments on radiosynovectomy with 166Ho FHMA
Our results indicate that 166Ho FHMA could at least temporarily halt the progress of
synovial proliferation, thereby decreasing the risk of OA development. MRI studies
suggest that the aim of RSYN should be effective long-term suppression of synovial
inflammation (Alonso-Ruiz et al., 1998; Pirich et al., 1999). In a clinical study in man,
166Ho FHMA was efficacious in controlling the symptoms of RA (Ofluoglu et al., 2002).
However, clinical studies were beyond the scope of this work. Moreover, intra-articular
effects of treatment might be different for equine and human joints. Finally, problems
associated with dose and with unequal distribution and radiosynovectomy effects on
synovial tissues need to be solved before 166Ho FHMA can be implemented for manage-
ment of synovitis in equine practice.
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CONCLUSIONS
Based on the results of these studies, the following conclusions can be made:
(i) Total synovectomy was not achieved even with a high dose of 166Ho FHMA to normal
equine and rabbit joints. The aim of 166Ho FHMA treatment should be effective 
suppression of synovial lining hyperplasia. 
(ii) 166Ho FHMA is distributed nonuniformly along the synovium, imparting high concen-
trations to some areas of the synovium and leaving others untouched. 166Ho FHMA is 
retained well inside the joint for at least 2 days, and the subsequent risk of extra-articular
radiation is small due to the short half-life of 166Ho.
(iii) Articular cartilage was not markedly affected by 166Ho FHMA treatment. Mild
cartilage fibrillation and temporary downregulation of Sox9 and aggrecan genes had
no permanent consequences on young rabbit cartilage. In adult horses, transient down
regulation of type II collagen synthesis and a slight reduction in the size of aggrecan
monomers had no obvious effect on biochemical or morphological properties of 
articular cartilage.
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